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Diclofenac potassium is an anti-inflammatory agent classified as a class II drug as per the biopharmaceutical 
classification system (BCS). The poor dissolution rate of water-insoluble drugs is still a major problem 
confronting the pharmaceutical industry. There are several techniques to enhance the dissolution of poorly 
soluble drugs. Methods available include salt formation, micronization and addition of solvent or surface active 
agents. The objective of the present work is to improve the dissolution profile of diclofenac potassium by 
formation of a physical mixture and a solid dispersion with mannitol. The solid dispersion was prepared by 
solvent method using ethanol/water. As diclofenac potassium melts with decomposition, the compatibility study 
with mannitol was done with the acid form by differential scanning calorimetry (DSC). The dissolution 
properties and physicochemical properties of diclofenac potassium:mannitol physical mixture and solid 
dispersion were investigated by Powder X-ray Diffraction (PXRD), Fourier Transform Infrared Spectroscopy 
(FTIR), Scanning Electron Microscopy (SEM) and dissolution test. This study shows that the dissolution rate of 
diclofenac potassium can be enhanced considerably by formulating it with mannitol, as a physical mixture or as 
a solid dispersion although crystallinity was maintained.  
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INTRODUCTION 
 
Diclofenac is commercially present as sodium and 
potassium salt in tablets for oral administration and as 
diethylamine for topical application. While extensive literature is 
available for sodium salt little has been reported on the potassium 
salt (Fini et al., 2001). The solid dispersion technique for water-
insoluble drugs developed by Chiou and Reigelman (Chiou and 
Reigelman, 1971) provides an efficient method to improve the 
dissolution rate of a drug (Ford, 1986; Leuner and Dressman, 
2000; Frizon et al., 2013). In solid dispersion systems, a drug 
may exist as an amorphous form in polymeric carriers, and this         
.  
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may result in improved solubilities and dissolution rates as 
compared with crystalline material. Several investigators have 
proposed the mechanisms for the enhancement of the dissolution 
rate of solid dispersions. Drugs molecularly dispersed in polymeric 
carriers may achieve the highest levels of particle size reduction 
and surface area enhancement, which result in improved 
dissolution rates (Craig, 2002). Furthermore, no energy is required 
to break up the crystal lattice of a drug during dissolution process 
(Taylor and Zografi, 1997), and drug solubility and wettability 
may be increased by surrounding hydrophilic carriers (Craig, 
2002). The methods used to prepare solid dispersions include the 
melting method, the solvent method and the solvent wetting 
method (Leuner and Dressman, 2000; Yamashita et al., 2003). 
However, the melting method and the solvent method have some 
limitations. In the case of the melting method, incomplete 
miscibility between drug and carrier may occur due to the high           
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viscosity of a polymeric carrier in the molten state and thermally 
unstable drugs can be degraded due to the requirement of 
relatively high preparation temperatures. In the case of the solvent 
method, since both drug and carrier must be dissolved completely 
in organic solvent, subtle alterations in the conditions used for 
solvent evaporation may lead to large changes in product 
performance (Leuner and Dressman, 2000; Moneghini et al. 
1998). The solvent method also introduces residual solvent, which 
may bring up the environmental issues.  
Mannitol was used to increase the aqueous solubility and 
dissolution of different drugs (Rajko et al., 2009; Zajc et al., Arias 
et al., 1995; 2005; Arias et al., 1998). Diclofenac potassium has 
been classified as a class II drug as per the biopharmaceutical 
classification system (BCS) (Chuasuwan et al., 2009).  
The objective of the present work is to improve the 
dissolution profile of diclofenac potassium by formation of a 
physical mixture (PM) and a solid dispersion (SD) with mannitol. 
The solid dispersion was prepared by solvent method using 
ethanol/water.  
As diclofenac potassium melts with decomposition, the 
compatibility study with mannitol was done with the acid form by 
differential scanning calorimetry (DSC). The dissolution 
properties and physicochemical properties of diclofenac 
potassium:mannitol physical mixture and solid dispersion were 
investigated by Powder X-ray Diffraction (PXRD), infrared 
spectrometry (FTIR), scanning electron microscopy (SEM), and 
dissolution test. 
 
MATERIALS AND METHODS 
 
Materials 
Mannitol (purity ≥ 99.0 %) was received as a gift sample 
from Merck S.A. (Merck, Germany). Diclofenac potassium (purity 
99.9 %) was purchased in Saporiti, Argentina. Methanol used was 
HPLC grade, Sintorgan (Buenos Aires, Argentina) and monobasic 
sodium phosphate AR Grade, J. T. Baker (Estado de Mexico, 
Mexico). Distilled water was passed through a 0.45 µm membrane 
filter. All the solvents and reagents used were of analytical or 
HPLC reagent grade. 
 
Preparation of physical mixture and solid dispersion 
Physical Mixture 
A PM of 5 g of diclofenac potassium and mannitol (1:1) 
by weight was prepared by mixing with spatula in a mortar until a 
homogeneous mixture was obtained. The resulting mixture was 
sieved through a # 80 sieve 
 
Solid dispersion prepared by solvent evaporation 
A mixture of 5 g of diclofenac potassium and mannitol 
(1:1) by weight respectively was wetted with water-ethanol (1:1 
ratio) The solvent was evaporated under reduced pressure at 40 °C, 
and the resulting residue was dried under vacuum for 3 h, stored in 
a desiccator at least overnight, ground in a mortar, and passed 
through a # 80 sieve. 
Diclofenac Acid (for DSC)  
The free acid was obtained by dissolving diclofenac 
potassium in water and lowering the pH using perchloric acid 
0.01N until pH:3.0. The precipitate was recovered by vacuum 
filtration. The precipitate was washed with distilled water until 
neutrality and then, dried at 40 °C under vacuum using a vacuum 
oven.  
 
Analysis of the active ingredient 
The liquid chromatographic method was carried out on a 
Merck LiChrospher 100 RP-8, 10µm 250 x 4.6 mm and detection 
was performed at 254 nm. The mobile phase consisted of 0.01M 
monobasic sodium phosphate buffer:methanol (30:70 v/v), pH 
adjusted to 2.5 using phosphoric acid. The flow rate was 1 mL/min 
and was maintained at room temperature. The chromatographic 
separation was obtained with retention time of 6.0 min. The 
injection volume was 20 µL. The HPLC system consisted of a dual 
piston reciprocating Thermo Finnigan pump, a Rheodyne injector, 
a DAD Dionex Ultimate 3000 with operating software 
Chromeleon 6.8 was used during the study. 
 
Preparation of standard solution 
An accurately weighed quantity of 75 mg of diclofenac 
potassium was dissolved in 25 mL of a mixture methanol:water 
(70:30) (diluent solution). One mL aliquot of the solution was 
transferred to a 10 mL volumetric flask, diluted to volume  with 
diluent solution. The solutions were passed through a 0.45 µm 
nylon membrane filter before injection (25 mm disposable filter; 
Cat. N° R04SP02500 Osmonics Inc., Minnesota, USA). 
 
Sample Preparation 
Approximately 150 mg of the SD or the PM were exactly 
weighed, placed into a 25 mL volumetric flask, taken to volume 
with diluent solution. One mL aliquot of the solution was 
transferred to a 10 mL volumetric flask, diluted to volume  with 
diluent solution. The solutions were passed through a 0.22 µm 
nylon membrane filter before injection (25 mm disposable filter; 
Cat. N° R04SP02500 Osmonics Inc., Minnesota, USA). 
 
Differential scanning calorimetry (DSC) 
A differential scanning calorimeter (DSC 822, Mettler 
Toledo, Switzerland) was used for thermal analysis of drug and 
excipient. Individual samples (drug and excipient) as well as the 
physical mixture of the drug and the excipient were weighed 
directly in the pierced DSC aluminium pan and scanned in the 
temperature range of 30-350 °C under atmosphere of dry nitrogen. 
A heating rate of 10 °C/min was used and the obtained 
thermograms were observed for any interaction. The DSC cell was 
calibrated with indium (m.p. 156.6 °C; ΔHfus=28.5 Jg
-1
) and Zinc 
(m.p. 419.6 °C) as standards. Empty aluminium pans were used as 
references. Samples with mass 1-2 mg were employed, by 
duplicate. Data were treated with STARe software Ink. (Mettler 
Toledo, Switzerland). 
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Powder X-ray Diffraction (PXRD) 
PXRD were collected at RT using a D8 Advance X-ray 
diffractometer (Bruker AXS, Germany). The target was Copper-
tube ((Cu K radiation Ɵ = 1.5418 Å) and a post-diffraction 
graphite monochromator. The X-ray generator was set at a voltage 
of 40 kV and current of 40 mA. Samples were subject to PXRD 
analysis in step mode with a step size of 0.05º 2Ɵ and a step time 
of 3 s over an angular range of 2-50º 2Ɵ. The sample holder was 
rotated in a plane parallel to its surface at the speed of 30 rpm 
during the measurements. Obtained diffractograms were analyzed 
with DIFFRACplus EVA diffraction software. 
 
Fourier Transform Infrared Spectroscopy (FTIR) 
Infrared spectra (4000-400 cm
–1
) were recorded on a 
Nicolet iS10 FT-IR spectrometer Thermo Scientific. Solid samples 
were placed over a diamond attenuated total reflectance (ATR) 
accessory (Smart iTR), without any grinding or KBr. The spectra 
were collected with 32 scans, at 4 cm
-1 
resolution. 
 
Scanning electron microscopy 
Electron micrograph of potassium diclofenac, mannitol, 
PM and SD were obtained using scanning electron microscope 
(SEM) Carl Zeiss Σigma at the Laboratorio de Microscopía y 
Análisis de Rayos X (LAMARX) of the National University of 
Córdoba. The samples were sputtered with gold using a Balzers 
model SDC 030. Micrographs with different magnifications were 
recorded to study the morphology of the samples. 
 
Dissolution rate studies 
Dissolution studies were performed using USP 38 (The 
United States Pharmacopeia, 2015) Apparatus 2 (Vankel, VK 
7010). The pure drug,  PM and  SD  were placed in capsules N° 0. 
The diclofenac potassium content in PM and SD was normalized 
by HPLC and the equivalent of 75 mg was placed in each capsule.   
Tests were carried out with twelve units and were performed at 50 
± 1 rpm. Dissolution media was phosphate buffer pH 6.8 at 37 ± 
0.5 °C. Dissolution media volume was 900 ml. In all experiments, 
10 ml sample aliquots were withdrawn at 10, 15, 20, 30 and 45 
min using syringes. All samples were filtered through blue ribbon 
filter paper. The amount dissolved was calculated by determining 
the absorbance of an appropriately diluted solution at 276 nm.  
 
 
RESULTS AND DISCUSSION 
 
Diclofenac potassium melts with decomposition (Fini et 
al., 2001). Diclofenac potassium thermogram indicated that the 
starting material corresponds to the dehydrated form (Figure 1). 
The compatibility study with mannitol was done with the acid 
form by differential scanning calorimetry (DSC). The thermogram 
of diclofenac (acid form) exhibited a single, sharp, endothermic 
peak at temperature of 164.23 °C, mannitol exhibited a melting 
point of 165.14 °C and the mixture exhibited a melting point of 
165.03 °C, as the addition of both peaks (Figure 2). The melting 
endotherm of diclofenac acid was well retained in the blend with 
mannitol. T 
 
 
Fig. (1). DSC of  Diclofenac potassium 
 
 
 
Fig. (2). DSC of Diclofenac (acid form), Mannitol, and Diclofenac (acid 
form):Mannitol 1:1 physical mixture. 
 
The enthalpy value of  PM  is reduced to half the sum of 
the endotherms of diclofenac (acid form) and mannitol  (Table I). 
The minor changes in the melting endotherm of the mixture could 
be attributed to the mixing of active and excipient, and not indicate 
potential incompatibility. Variations in the enthalpy values for the 
binary mixtures can be attributed to some heterogeneity in the 
small samples used for the experiments (3-4 mg) (Verma et al., 
2005). 
 
Table 1 Peak temperature and enthalpy values  
Samples Tonset  (°C) Tpeak (°C) ΔH  (Jg
-1
) 
Diclofenac (acid form) 153.85 164.23 -87.85 
Mannitol 163.51 165.14 -303,95 
Physical mixture 162.91 165.03 -162.19 
 
The X-Ray diffractometry showed that pure diclofenac 
potassium, diclofenac potassium within  PM and diclofenac 
potassium in  SD  were crystalline in nature (Figure 3). The pure 
diclofenac potassium showed the characteristics diffraction peaks 
at 2Ɵ of 14.4, 15.3, 16.5, 21.7, 25.3, 26.1, 27.0, and 27.9º etc., 
indicating the presence of crystalline diclofenac potassium. This 
powder pattern was concordant with the dehydrated form reported 
by Fini  (Fini et al., 2005). 
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Fig. (3). Powder X-ray diffraction patterns of 1:1 Diclofenac potassium-
Mannitol test preparation. Key: A, raw Diclofenac K; B, physical mixture; C, 
solid dispersion, D, raw Mannitol. ^ Mannitol polymorph Beta. * Mannitol 
polymorph Alpha. 
 
The pure mannitol showed the characteristics diffraction 
peaks at 2Ɵ of 9.7, 19.5, 20.4, 22.1, 24.7, 25.3, 36.1, 40.4 and 
44.9º etc., indicating the presence of crystalline mannitol, 
polymorphic form Delta with monoclinic (P21) crystal structure as 
the mayor phase. The minor peaks observed at 14.6, 18.8 and 23.4º 
2Ɵ correspond to mannitol polymorph Beta (Orthorrombic, 
P212121) present as an impurity crystalline phase (Fronczek, 2003).  
The PM also showed crystallinity, due to the presence of 
crystalline diclofenac potassium and mannitol. Thus, the mere 
presence of mannitol in PM should not interfere with the 
characterization of coexisting diclofenac potassium. The X-ray 
diffraction pattern of PM was a superimposition of each 
component. 
In case of the 1:1 ratio diclofenac potassium-mannitol  
SD also showed crystallinity, due to the presence of diclofenac 
potassium and mannitol. The X-ray diffraction pattern showed all 
reflections corresponding to crystalline diclofenac potassium, but 
distinct differences in another peak positions. As a result of 
reviewing the polymorphic forms of mannitol (Fronczek, 2003), it 
was possible to identify a mixture of polymorphs Beta 
(characteristic peaks at 10.5, 14.6, 18.8, 20.5, 21.2 and 23.4º 2 Ɵ) 
and Alpha (characteristic peaks at 9.4, 13.7, 17.3, 18.7, 19.8, 20.4 
and 43.9º 2 Ɵ) present in the SD sample. 
This result implies that diclofenac potassium and 
mannitol are present in crystalline form in the 1:1 diclofenac 
potassium-mannitol PM and SD. Thus, there was no additional 
amorphization of the drug and which retained its original 
crystalline form, although mannitol polymorph Delta was 
transformed to a mixture of polymorphs Beta and Alpha in the SD. 
The FTIR spectrum of pure diclofenac potassium showed a band at 
3248 cm
-1
 due to the N-H stretching, a band at 2973 cm
-1 
due to the 
C-H stretching, a band at 1575 cm
-1
 due to C=O stretching, two 
typical bands at 1305 and 1449 cm
-1
 relative to the C-C stretching, 
and at 745 cm
-1
 owing to C-Cl stretching. 
Mannitol shows a broad absorption band at 3229 cm
-1
 
assigned to the hydroxyl groups. The spectra obtained from the 1:1 
ratio PM presented band assignments at the same wavelength 
ranges depicting no interaction between the drug and mannitol 
The SD containing the 1:1 drug-mannitol showed that there was no 
shifting of the principal shoulders and the maximum of the drug 
with the use of mannitol. This confirms that there was no 
interaction between the drug and the mannitol used.  
Scanning electron microscopy (SEM) (Figure 4) shows 
the aggregation of smaller crystals of pharmaceutically available 
diclofenac potassium (Fig 4 A) whereas mannitol has irregular 
sticks with a median volume diameter (Fig 4 B) and these two 
different crystal shapes can be easily identified in the physical 
mixture (Fig 4 C). It was observed that the solid dispersion sample 
obtained from methanol:water (70:30) contained crystalline 
particles with a smooth surface and a unique surface morphology 
different from diclofenac potassium and mannitol particles (Fig 4 
D). This suggests that the two components were homogeneously 
distributed and a solid solution was formed which could be 
responsible for the increased dissolution rate of diclofenac 
potassium. 
 
 
Fig. (4). Photographs (SEM of 10 µM) Key: A, Diclofenac potassium; B, 
Mannitol;  C, physical mixture; D, solid dispersion. 
 
The effect of mannitol on the dissolution of diclofenac 
potassium was investigated. The pure drug dissolved 
approximately 60% in this condition. The dissolved amounts of 
diclofenac potassium from the 1:1 diclofenac potassium-mannitol 
PM increased 34% compared with the pure drug. The diclofenac 
potassium:mannitol (1:1) SD increased the dissolved amount in 
41% compared with the pure drug. Figure 5 shows the percent 
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dissolved in function of the time, presenting the Standard deviation 
values at each time point of the dissolution testing. 
 
 
Fig. (5).  Dissolution profiles 
 
CONCLUSIONS 
 
The solid dispersion of diclofenac potassium and 
mannitol was prepared using solvent evaporation. The physical 
mixture was prepared by thoroughly mixing appropriate amount of 
diclofenac potassium and mannitol in a mortar until a 
homogeneous mixture was obtained. The data obtained from DSC 
and FT-IR showed no significant drug-carrier interactions. 
PXRD results indicated that diclofenac potassium is in 
crystalline form both in PM and SD, while mannitol (δ polymorph) 
experienced a polymorphic transformation in the SD (polymorphs 
β and α). 
This study shows that the dissolution rate of diclofenac 
potassium can be enhanced considerably by formulating it with 
mannitol, as a PM or as a SD in comparison with the pure drug. In 
both cases, crystallinity was maintained. 
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